Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 12:10:765.
doi: 10.3389/fonc.2020.00765. eCollection 2020.

Update on Biology of Cutaneous T-Cell Lymphoma

Affiliations
Review

Update on Biology of Cutaneous T-Cell Lymphoma

Zaw H Phyo et al. Front Oncol. .

Abstract

Cutaneous T cell lymphomas (CTCL) comprise of a heterogeneous group of non-Hodgkin lymphomas derived from skin-homing T cells. Variation in clinical presentation and lack of definitive molecular markers make diagnosis especially challenging. The biology of CTCL remains elusive and clear links between genetic aberrations and epigenetic modifications that would result in clonal T cell expansion have not yet been identified. Nevertheless, in recent years, next generation sequencing (NGS) has enabled a much deeper understanding of the genomic landscape of CTCL by uncovering aberrant genetic pathways and epigenetic dysregulations. Additionally, single cell profiling is rapidly advancing our understanding of patients-specific tumor landscape and its interaction with the surrounding microenvironment. These studies have paved the road for future investigations that will explore the functional relevance of genetic alterations in the progression of disease. The ultimate goal of elucidating the pathogenesis of CTCL is to establish effective therapeutic targets with more durable clinical response and treat relapsing and refractory CTCL.

Keywords: cutaneous T cell lymphoma (CTCL); mycosis fungoides; next generation sequencing; precision medicine; sezary syndrome; single cell profiling; tumor microenvironment.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. (2016) 91:151–65. 10.1002/ajh.24233 - DOI - PMC - PubMed
    1. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. (2007) 143:854–9. 10.1001/archderm.143.7.854 - DOI - PubMed
    1. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. . Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International society for cutaneous lymphomas/European organisation for research and treatment of cancer staging proposal. J Clin Oncol. (2010) 28:4730–9. 10.1200/JCO.2009.27.7665 - DOI - PubMed
    1. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. (2009) 113:5064–73. 10.1182/blood-2008-10-184168 - DOI - PMC - PubMed
    1. Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins RD. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol. (1988) 132:265–77. - PMC - PubMed

LinkOut - more resources